Primary Progressive Aphasia Clinical Trial
Official title:
Treating Primary Progressive Aphasia and Apraxia of Speech With High Definition Transcranial Direct Current Stimulation (HDtDCS-PPA/PAOS)
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., pre-supplementary motor area) thought to aid in memory will improve speech and language difficulties in patients with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS). The primary outcome measures are neuropsychological assessments of speech and language functions, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures.
This pilot study has one treatment arm with open-label treatment and will examine improvement of speech output, verbal fluency, and other cognitive deficits associated with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS), by utilizing 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to pre-supplementary motor area for 20 minutes over 10 sessions. There will be baseline testing, and follow up testing immediately after and 8 weeks after completion of treatment. All patients with a clinical diagnosis of PPA or PAOS will be assigned to one open-label group to receive active tDCS. Primary outcome speech and language measures, secondary neuropsychological and electroencephalography (EEG) measures, and pre-screening assessments for study medical history and contraindications for treatment will be collected prior to the treatment (i.e., baseline). Primary outcome speech and language functions measures and secondary neuropsychological and electroencephalography (EEG) measures will be collected after treatment session 10 and following treatment competition (i.e., 8-week). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT04290988 -
Circuitry Assessment and Reinforcement Training Effects on Recovery
|
N/A | |
Recruiting |
NCT04957537 -
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia
|
N/A | |
Completed |
NCT04045990 -
Network Modulation in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05443633 -
Enhancing Language Function in Aphasia
|
N/A | |
Completed |
NCT05860647 -
Transmagnetic Stimulation Pilot in Primary Progressive Aphasia
|
N/A | |
Recruiting |
NCT03887481 -
Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA
|
N/A | |
Completed |
NCT03728582 -
Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy
|
N/A | |
Completed |
NCT01465360 -
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
|
N/A | |
Completed |
NCT02541097 -
Preventing Language Decline in Dementia
|
N/A | |
Recruiting |
NCT00537004 -
Language in Primary Progressive Aphasia
|
||
Recruiting |
NCT05741853 -
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
|
N/A | |
Active, not recruiting |
NCT05742698 -
Nabilone for Agitation in Frontotemporal Dementia
|
Phase 2 | |
Completed |
NCT02439853 -
Communication Bridge Speech Therapy Research Study
|
N/A | |
Completed |
NCT01623284 -
PiB PET Scanning in Speech and Language Based Dementias
|
Phase 1 | |
Completed |
NCT04726527 -
Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
|
||
Completed |
NCT03076671 -
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
|
N/A | |
Completed |
NCT05537688 -
Identification of Graphic Markers of Neurocognitive Disorders (MG)
|
||
Completed |
NCT05525377 -
Better Living With Non-memory-led Dementia
|
N/A | |
Completed |
NCT02928848 -
Transcranial Direct Current Stimulation for Primary Progressive Aphasia
|
N/A | |
Completed |
NCT04939818 -
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
|